Alteplase

Alteplase
Clinical data
Trade names	Activase, Actilyse, Cathflo Activase, others
Other names	t-PA, rt-PA
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Alteplase;
Pregnancy; category	AU: B1; ;
Routes of; administration	Intravenous
ATC code	B01AD02 (WHO) S01XA13 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	105857-23-6 ;
DrugBank	DB00009 ;
ChemSpider	none;
UNII	1RXS4UE564;
KEGG	D02837 ;
Chemical and physical data
Formula	C2569H3928N746O781S40
Molar mass	59042.52 g·mol−1
	(verify)

Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter.^[5] It is given by injection into a vein or artery.^[5] Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells^[6] and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis.^[7]

^ Australian Public Assessment Report for Alteplase (AusPAR) (PDF). Therapeutic Goods Administration (TGA) (Report). February 2011.
^ Cite error: The named reference Activase FDA label was invoked but never defined (see the help page).
^ Cite error: The named reference Cathflo Activase FDA label was invoked but never defined (see the help page).
^ "Actilyse". European Medicines Agency. 17 September 2018. Archived from the original on 17 November 2020. Retrieved 14 November 2020.
^ ^a ^b "Alteplase Monograph for Professionals". Drugs.com. Archived from the original on 27 August 2020. Retrieved 11 November 2019.
^ Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, et al. (July 2009). "Management of occlusion and thrombosis associated with long-term indwelling central venous catheters". Lancet. 374 (9684): 159–69. doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
^ Cite error: The named reference :6 was invoked but never defined (see the help page).
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.